TOLEDO, Ohio & NEW YORK--(BUSINESS WIRE)-- NAMSA, the world’s only 100% medical device-focused Contract Research Organization (CRO) providing full continuum development solutions, announced today its acquisition of New York-based CRO, Syntactx. This acquisition follows independent healthcare investment firm ArchiMed’s majority interest purchase of NAMSA in September 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210105005084/en/

Syntactx, founded in 2010, has a rich history and proven track record of synthesizing clinical evidence for global medtech Sponsors to enable broad market adoption and commercial success of innovative medical products. Having enrolled over 200,000 trial subjects within the last ten years, Syntactx possesses significant expertise in complex interventional medical device trials and a deep-rooted understanding of enrollment obstacles and regulatory challenges and obligations.

As the pioneer of the medical device testing industry, NAMSA provides testing services to Sponsors, in addition to quality, reimbursement, clinical research and regulatory solutions. The CRO’s end-to-end development services are shown to help Sponsors successfully address varying global requirements, including recently expanded criteria for medical device research and conduct (e.g. MDR/IVDR), resulting in increased regulatory oversight and clinical evidence requirements.

“This is a very exciting day for NAMSA, and I couldn’t be more pleased that Syntactx is joining the NAMSA family,” stated John Gorski, NAMSA President and CEO. “Not only are our values and cultures well-aligned, but both organizations have a strong commitment to enhancing patient healthcare by safely and judiciously helping clients deliver innovative, life-changing medical devices to the global marketplace,” he concluded.

Most notably, NAMSA’s acquisition of Syntactx will enhance the company’s already robust cardiovascular-focused regulatory consulting and clinical research solutions, while expanding Electronic Data Capture (EDC), core lab imaging, safety and physician consulting service offerings. These areas are key to further strengthening NAMSA’s rich history of assisting Sponsors to proactively tackle development challenges head-on, achieve commercialization success and positively impact patient lives.

“Syntactx is very proud to join NAMSA, a long-recognized industry leader in CRO medical device development and clinical research services,” stated Dr. Kenneth Ouriel, President and CEO of Syntactx. “Syntactx’s corporate goals are wholly aligned with those of NAMSA. Relying on the latest technologies, a client-focused approach and leveraging longstanding, trusted relationships with regulatory agencies and investigational sites, together, we will provide a range of services and level of quality unsurpassed in the global CRO industry.”

About NAMSA

Helping medical device Sponsors improve healthcare since 1967, NAMSA is the world’s only 100% medical device-focused, full continuum Contract Research Organization (CRO). Driven by its global regulatory expertise and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development, offering only the most proven solutions to move clients’ products through the development lifecycle efficiently and cost-effectively. From medical device testing; regulatory, reimbursement and quality consulting; and clinical research services; NAMSA is the industry’s premier, trusted partner for successful development and commercialization outcomes. Web: namsa.com

About Syntactx

Founded in 2010, Syntactx is a Clinical Research Organization (CRO) with expertise in complex interventional medical device and pharmaceutical trials across multiple therapeutic areas. Syntactx has a long history of synthesizing clinical evidence to enable broad market adoption of innovative products. We are committed to elevating global health by setting a new standard in complex clinical research through best-in-class service, therapeutic expertise, and technology.
Web: syntactx.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005084/en/